Sylvia Varela, head of AstraZeneca Mexico, said at the Mexican president's daily news conference that Phase III trials were expected to conclude by November or December.
(Reporting by Raul Cortes and Daina Beth Solomon; Editing by Dave Graham)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12,050 GBX | -0.87% | +0.52% | +13.68% |
03/05 | Angle shares up on assay development deal with AstraZeneca | AN |
03/05 | Angle shares up on assay development deal with AstraZenaca | AN |
Production of a COVID-19 vaccine under an agreement between the Mexican and Argentine governments and pharmaceutical company AstraZeneca could begin in the first quarter of 2021, an AstraZeneca executive said on Thursday.
Sylvia Varela, head of AstraZeneca Mexico, said at the Mexican president's daily news conference that Phase III trials were expected to conclude by November or December.
(Reporting by Raul Cortes and Daina Beth Solomon; Editing by Dave Graham)
1st Jan change | Capi. | |
---|---|---|
+13.68% | 234B | |
+26.08% | 662B | |
+21.85% | 546B | |
-4.77% | 359B | |
+16.97% | 323B | |
+5.69% | 290B | |
+3.65% | 198B | |
-11.12% | 194B | |
+8.08% | 167B | |
-3.40% | 157B |